Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 5/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484767 | 0.91 | PIM1 (0.38) | PIM1PIM3PIM2MAP2K1MAP2K2 | |
| SCHEMBL5481433 | 0.86 | MAP2K1 (0.39) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3883718 | 0.78 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5477634 | 0.76 | MAP2K1 (0.35) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL4052244 | 0.75 | MAP2K1 (0.33) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL5479878 | 0.75 | MAP2K1 (0.42) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3888960 | 0.73 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL3893004 | 0.72 | MAP2K1 (0.44) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL3887156 | 0.72 | MAP2K1 (0.47) | MAP2K1MAP2K2PRKCZIARS2 | |
| SCHEMBL6206815 | 0.70 | MAP2K1 (0.51) | PIM1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | PIM1 95/4885PIM3 172/4885PIM2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.